Kushen (Radix Sophorae Flavescentis) has a long history of use for the treatment of tumors, inflammation and other diseases in traditional Chinese medicine. Compound Kushen Injection (CKI) is a mixture of natural compounds extracted from Kushen and Baituling (Rhizoma Smilacis Glabrae). The main principles of CKI are matrine (MT) and oxymatrine (OMT) that exhibit a variety of pharmacological activities, including anti-inflammatory, anti-allergic, anti-viral, anti-fibrotic and cardiovascular protective effects. Recent evidence shows that these compounds also produce anti-cancer actions, such as inhibiting cancer cell proliferation, inducing cell cycle arrest, accelerating apoptosis, restraining angiogenesis, inducing cell differentiation, inhibiting cancer metastasis and invasion, reversing multidrug resistance, and preventing or reducing chemotherapy-and/or radiotherapy-induced toxicity when combined with chemotherapeutic drugs. In this review, we summarize recent progress in studying the anti-cancer activities of MT, OMT and CKI and their potential molecular targets, which provide clues and references for further study.
Introduction
There is a long history of the use of traditional Chinese medicines (TCMs) to treat solid tumors in China [1] . In the past several decades, many TCMs have been approved by the Chinese State Food and Drug Administration and used in the clinical treatment of various types of solid tumors [2] . An increasing number of anti-cancer agents have been identified from the study of TCMs, although most of their molecular mechanisms are still waiting elucidation.
TCMs have been widely used in combination with chemotherapy or radiotherapy to improve the efficacy of cancer therapy and reduce side effects and complications [3] . Many years of clinical trials in China have shown that TCMs can modulate immune function and improve the quality of life of cancer patients, particularly for patients undergoing che-motherapy [4] . Most TCM formulas are mixtures of different natural compounds, which might function in different ways and target different molecular pathways [5] . An emerging approach in biomedical research, systems biology, is a systemlevel analysis that focuses on complex interactions within biological systems [6] . Carcinogenesis is a complicated process of cell transformation by a progression of changes at the cellular, genetic and epigenetic levels [7, 8] . Therefore, systems biology might shed light on the molecular mechanisms of the anticancer effects of TCMs, which may inspire the rethinking of the modern treatment of cancer.
Compound Kushen Injection (CKI) is a mixture of natural compounds extracted from two medical herbs: Kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma Smilacis Glabrae). Kushen has a long history of use for the treatment of solid tumors, inflammation and other diseases [1] . The primary compounds found in CKI are matrine, oxymatrine and sophoridine [9, 10] . Here we will introduce the anti-cancer effects of matrine and oxymatrine because there is little research about sophoridine. [11] . All of these studies indicated that matrine could inhibit cancer cell proliferation and induce apoptosis via different molecular pathways.
Matrine was reported to effectively inhibit the proliferation of breast cancer cells, including ER-positive MCF cells, HER2-positive BT-474 cells and highly metastatic MDA-MB-231 cells. The death of cancer cells was observed in the matrine treatment group. The expression of the inhibitor of κB (IκB) kinase β (IKKβ) was downregulated by matrine in the NF-κB signaling pathway [12] . Another study indicated that matrine might suppress breast cancer cell (MCF-7) growth by inducing apoptosis and cell cycle arrest at the G 1 /S phase in a dose-and time-dependent manner via the miR-21/PTEN/Akt pathway. Matrine might repress the expression of miR-21, which can target and down-regulate the tumor suppressor PTEN. The upregulation of PTEN dephosphorylates Akt, resulting in an accumulation of Bad, p21/WAF1/CIP1 and p27/KIP1, which trigger intrinsic apoptotic cascades [13] . Matrine can also inhibit cell proliferation and induce apoptosis in a dose-and time-dependent manner in gastric carcinoma cells (SGC-7901). The expression of Fas/Fasl and the activity of caspase-3 enzyme increased after treatment with matrine, and these changes were highly correlated with the apoptosis rate [14] . Another study used matrine to treat human gastric cancer cells (MKN45). In that study, matrine activated the caspase-3 and -7 pathways and increased the pro-apoptotic molecules of the Bcl-2 family (Bok, Bak, Bax, Puma, and Bim) to inhibit cell proliferation and induce apoptosis in a dosedependent manner [15] . The treatment of human gallbladder carcinoma cells (GBC-SD) with matrine was associated with an inhibition of cancer cell growth, induction of G 1 cell cycle arrest and activation of apoptosis in a dose-and time-dependent manner. Apoptosis was activated by the down-regulation of the anti-apoptotic protein Bcl-2 and the upregulation of the pro-apoptotic protein Bax after the cancer cells were treated with matrine [16] . The dose-and time-dependent inhibition of cell growth and the induction of apoptosis were also observed in rat osteosarcoma UMR-108 cells (bone tumor) after treatment with matrine. It has been demonstrated that matrine can disrupt the mitochondrial transmembrane potential and upregulate reactive oxygen species. The downregulation of Bcl-2 and the upregulation of Bax were observed in matrine-treated UMR-108 cells, in which apoptosis was subsequently activated [17] . In addition to the functional roles of inhibiting cell proliferation and inducing G 1 -phase cell cycle arrest and apoptosis that have been reported in other cancer cells, matrine can also activate autophagy in human HepG2 cells in a dose-dependent manner. After treatment with matrine, abundant cytoplasmic vacuoles of different sizes were observed and vacuolization progressively became larger and denser with the increase of concentration of matrine in HepG2 cells. The results from treatment with the specific autophagic inhibitor 3-MA by electron microscopy confirmed the effect of matrine in inducing autophagy [18] . The anti-tumor effect of matrine on murine hepatocellular carcinoma H22 cells was also demonstrated, and the inhibition of cell proliferation and the activation of apoptosis were proposed as the likely mechanisms [19] . Matrine can also inhibit cell viability and induce cell apoptosis in human acute myeloid leukemia (AML) cells in a doseand time-dependent manner. After treatment with matrine, apoptosis in AML cells was induced by collapsing the mitochondrial membrane potential, inducing cytochrome c release from mitochondria, reducing the ratio of Bcl-2/Bax, increasing the activation of caspase-3, and decreasing the levels of p-Akt and p-ERK1/2 [20] . In K562 cells, matrine was shown to inhibit cell proliferation and induce apoptosis via the mitochondrial pathway in a time-and dose-dependent manner. Analyses showed that E2F-1 and Apaf-1 were upregulated and that caspase-9 and -3 were activated after the exposure to matrine [21] . Li et al [22] identified 128 miRNAs exhibiting >2-fold expression changes in matrine-treated cells relative to their expression levels in untreated cells. The data revealed that the majority of the 57 identified enrichment pathways were highly involved in tumorigenesis. The treatment of breast cancer cells (MCF-7) with oxymatrine was associated with an inhibition of cell proliferation and a decrease in the number of stem cell-like side population (SP) cells. The anti-cancer effect of oxymatrine on MCF-7 cells may be due to the inhibition of the Wnt/β-catenin signaling pathway [23] . Oxymatrine can also induce apoptosis in human pancreatic cancer PANC-1 cells by a mechanism similar to matrine. After treatment with oxymatrine, livin and survivin genes were down-regulated and the Bax/Bcl-2 ratio was increased, accompanied by the release of mitochondrial cytochrome c and the activation of caspase-3 protein in PANC-1 cells [24] . It is also suggested that oxymatrine combined with angiogenesis inhibitor NM-3 has a synergistic inhibitory effect on the growth of human gastric cancer SGC-7901, MKN-45, and MKN-74 cells in a time-dependent manner.
Anti-cancer effects of oxymatrine
Semi-quantitative PCR analyses showed that oxymatrine in combination with NM-3 can induce apoptosis by downregulating the expression of Survivin and Bcl-2 and upregulating the expression of p53 mRNA [25] . The downregulation of the bcl-2 gene and the upregulation of the p53 gene were also observed in human hepatoma cells after treatment with oxymatrine. A significant cell cycle blockage in the G 2 /M and S phases was detected in oxymatrine-treated human hepatoma SMMC-7721 www.nature.com/aps Wang W et al Acta Pharmacologica Sinica npg cells, which might explain the inhibition of cell proliferation [26] .
Studies on Compound Kushen Injection
CKI has been widely used in clinical trials, and there are many clinical reports demonstrating its anti-cancer effect. These reports include using CKI to treat gastric cancer, liver cancer, lung cancer, breast cancer, ovarian cancer, colorectal cancer and other cancer types [11] . Recently, the mechanisms of CKI used as anti-cancer therapy were investigated. The in vitro and in vivo analyses of CKI in human breast cancer MCF-7 cells showed that CKI could inhibit the growth of MCF-7 stem-like SP cells. The size of SP cells was suppressed, and the primary genes of the Wnt signaling pathway, such as β-catenin, cyclinD1, and c-Myc, were downregulated after treatment with CKI. This may also explain how CKI can attenuate the side effects of chemotherapy; chemotherapeutic drugs only inhibit non-SP cells (differentiated cells), not cancer stem-like cells (SP cells) [26] . In another study, CKI had an anti-inflammatory effect, protecting against carcinogen-induced oxidative damage, which inhibits rat gastric carcinogenesis [27] . CKI has a significant anti-tumor effect on H22 and hepatic cancer, Lewis lung cancer and S180 tumors. In addition, it has synergistic and attenuation actions with anti-tumor agents in H22 and S180 cancer cells. The anti-tumor mechanisms of CKI may include: (1) increased protein expression of p16; (2) reduced unmethylated state of the p16 gene; (3) inhibited VEGF and MVD expression in neoplastic tissues; (4) decreased microvessel density [11, 27, 28] . Zhou et al [28] investigated the effects of CKI on gastric immunity and oxidantantioxidant status during N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastric carcinogenesis. They found that the administration of CKI significantly enhanced serum IgA, IgG, IgM, IL-2, IL-4, and IL-10 levels; decreased serum IL-6 and TNF-α levels; lowered the levels of lipid peroxides; and enhanced glutathione (GSH) levels and activities of GSHdependent enzymes. The authors suggested that CKI blocked experimental gastric carcinogenesis by protecting against carcinogen-induced oxidative damage and improving immunity activity.
Zhao et al state that CKI is a traditional Chinese medicine used alone or with chemotherapy to reduce cancer-associated pain. CKI treatment limited mouse sarcoma growth both in vivo and in vitro, in part by reducing the phosphorylation of ERK, AKT kinases and BAD. CKI inhibited TRPV1-mediated capsaicin-induced ERK phosphorylation and reduced tumorinduced pro-inflammatory cytokine production ( Figure  1 ). Thus, CKI limited cancer pain both directly by blocking TRPV1 signaling and indirectly by reducing tumor growth [29] . The efficacy of CKI has been evaluated in cancer patients either alone or in conjunction with chemotherapeutic or radiotherapeutic treatments. Shao et al reported that CKI combined with radiotherapy could significantly reduce adverse effects and improve the quality of life, the symptoms and the efficacy in elderly esophageal cancer patients [30] . Recently, Sun et al observed that CKI plus transcatheter arterial chemoembolization (TACE) is superior to TACE alone. They suggested that CKI could be a complementary drug with TACE to inhibit the growth of hepatocellular carcinoma, suppress tumor metastasis, reduce the incidence of pain and improve the quality of life in patients with unresectable hepatocellular carcinoma [31] . Bao et al have conducted a systematic literature research, which revealed a positive effect of CKI on bone cancer pain: compared with radiotherapy or bisphosphonates, CKI showed significant effects on the improvement of pain relief in patients with bone cancer pain and the increase in Karnofsky scores (KPS). The patients treated with CKI achieved statistically significant reductions in the incidence of leukopenia and nausea. No severe adverse events were found and no treatment was stopped because of adverse events of CKI in the treatment groups [32] . Many TCMs are a mixture of different natural compounds extracted from multiple medical herbs. In the past, most studies only focused on one or several extracted compounds. We have not seen studies using system-wide approaches to understand the molecular mechanisms of TCMs such as CKI. We hypothesize that the molecular mechanism underling the anticancer effect of CKI might involve altering gene regulation in several pathways.
